Citadel Advisors
ALXN

Citadel Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Citadel Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,100
Closed -$6.82M – 15333
2021
Q2 		$6.82M Sell
37,100
-4,000
-10% -$687K ﹤0.01% 3796
2021
Q1 		$6.29M Sell
41,100
-160,200
-80% -$24.8M ﹤0.01% 3788
2020
Q4 		$31.5M Sell
201,300
-215,800
-52% -$27.7M 0.01% 1355
2020
Q3 		$47.7M Buy
417,100
+212,200
+104% +$22.9M 0.01% 893
2020
Q2 		$23M Buy
204,900
+600
+0.3% +$63.7K 0.01% 1398
2020
Q1 		$18.3M Sell
204,300
-116,100
-36% -$11.4M 0.01% 1305
2019
Q4 		$34.7M Buy
320,400
+163,400
+104% +$17.5M 0.02% 1017
2019
Q3 		$15.4M Buy
157,000
+700
+0.4% +$78.9K 0.01% 1729
2019
Q2 		$20.5M Buy
156,300
+51,800
+50% +$6.68M 0.01% 1404
2019
Q1 		$14.1M Buy
104,500
+3,700
+4% +$460K 0.01% 1666
2018
Q4 		$9.81M Sell
100,800
-14,400
-13% -$1.7M 0.01% 1915
2018
Q3 		$16M Sell
115,200
-138,700
-55% -$17.4M 0.01% 1600
2018
Q2 		$31.5M Buy
253,900
+151,800
+149% +$17.7M 0.02% 960
2018
Q1 		$11.4M Buy
102,100
+42,700
+72% +$5.1M 0.01% 1592
2017
Q4 		$7.1M Sell
59,400
-169,200
-74% -$20.6M ﹤0.01% 2071
2017
Q3 		$32.1M Sell
228,600
-219,400
-49% -$29.8M 0.02% 788
2017
Q2 		$54.5M Buy
448,000
+392,000
+700% +$45.6M 0.05% 465
2017
Q1 		$6.79M Sell
56,000
-37,900
-40% -$4.89M 0.01% 1744
2016
Q4 		$11.5M Buy
93,900
+26,500
+39% +$3.24M 0.01% 1252
2016
Q3 		$8.26M Buy
67,400
+1,100
+2% +$142K 0.01% 1536
2016
Q2 		$7.74M Sell
66,300
-16,000
-19% -$2.27M 0.01% 1443
2016
Q1 		$11.5M Buy
82,300
+29,400
+56% +$4.32M 0.01% 1101
2015
Q4 		$10.1M Buy
52,900
+3,700
+8% +$646K 0.01% 1269
2015
Q3 		$7.69M Sell
49,200
-33,100
-40% -$6.04M 0.01% 1543
2015
Q2 		$14.9M Buy
82,300
+15,700
+24% +$2.71M 0.01% 1209
2015
Q1 		$11.5M Sell
66,600
-49,500
-43% -$8.96M 0.01% 1339
2014
Q4 		$21.5M Buy
116,100
+18,600
+19% +$3.45M 0.02% 893
2014
Q3 		$16.2M Buy
97,500
+18,600
+24% +$3.05M 0.02% 1040
2014
Q2 		$12.3M Sell
78,900
-44,800
-36% -$7.07M 0.01% 1110
2014
Q1 		$18.8M Sell
123,700
-127,500
-51% -$20.3M 0.02% 860
2013
Q4 		$33.4M Buy
251,200
+39,400
+19% +$4.73M 0.04% 539
2013
Q3 		$24.6M Buy
211,800
+79,800
+60% +$8.76M 0.04% 623
2013
Q2 		$12.2M Buy
+132,000
New +$12.7M 0.02% 940

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ALXN Position: Q3 2021 in Review

Citadel Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,248,848 shares — an estimated $597M sold.

Citadel Advisors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $597M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Citadel Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Citadel Advisors sold 3,248,848 Alexion Pharmaceuticals shares in Q3 2021, an estimated $597M.
  • Citadel Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Citadel Advisors's Alexion Pharmaceuticals position peaked at $597M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.